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ABSTRACT  
The 2019-nCoV is officially called SARS-CoV-2 and the disease is named COVID-19. The Novel coronavirus (SARS-CoV-2) caused pneumonia in 
Wuhan, China in December 2019 is a highly contagious disease. The World Health Organization (WHO) has declared it as a global public health 
emergency. This is the third serious Coronavirus outbreak in less than 20 years, following SARS in 2002–2003 and MERS in 2012. Currently, the 
research on novel coronavirus is still in the primary stage. It is currently believed that this deadly Coronavirus strain originated from wild 
animals at the Huanan market in Wuhan by Bats, snakes and pangolins have been cited as potential carriers. On the basis of current published 
evidence, we systematically summarize the epidemiology, clinical characteristics, diagnosis, treatment and prevention of COVID-19. This review 
in the hope of helping the public effectively recognize and deal with the novel coronavirus (SARS-CoV-2) and providing a reference for future 
studies. 
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1. Introduction 
There is a current worldwide outbreak of the novel 
coronavirus Covid-19 (coronavirus disease 2019; the 
pathogen called SARS-CoV-2; previously 2019-nCoV), which 
originated from Wuhan in China and has now spread to 7 
continents including 102 countries. Governments show their 
concern to stop the outbreak spreading into a global health 
emergency. Coronaviruses, a large family of single-stranded 
RNA viruses, can infect animals and also humans, causing 
respiratory, gastrointestinal, hepatic, and neurologic 
diseases1. As the largest known RNA viruses, CoVs are 
further divided into four generation: alpha-coronavirus, 
beta- coronavirus, gamma-coronavirus and delta-
coronavirus2. Now days there are six human coronaviruses 
(HCoVs) has been identified, including the alpha-CoVs 
HCoVs-NL63 and HCoVs-229E and the beta-CoVs HCoVs-
OC43, HCoVs-HKU1, severe acute respiratory syndrome-CoV 
(SARS-CoV)3, and Middle East respiratory syndrome-CoV 
(MERS-CoV)4. New coronaviruses appear to emerge 
periodically in humans, mainly due to the high prevalence 
and wide distribution of coronaviruses, the large genetic 
diversity and frequent recombination of their genomes, and 
the increasing of the human-animal interface activities5,6. 
2. Structure and genomes of Coronavirus  
Coronaviruses (CoVs) have crown-like spikes on their 
surface and belong to the family Coronaviridae within the 
order Nidovirales. Corona viruses broadly infect vertebrates 
including humans, birds, bats, snakes, mice and other wild 
animals7. Corona viruses (HCoVs) have been identified since 
mid-1960s8,9. Four commonly detected HCoVs are 229E, 
OC43, NL63 and HKU1. In one study, 229E and OC43 
accounted for approximately 15–29% of respiratory 
pathogens with relatively low virulence in humans10. 
Another epidemiological study in adults estimates that 
coronavirus causes about 15% of common colds11. Other 
significant causes of upper respiratory infections include 
influenza virus, rhinovirus, parainfluenza virus, Group A 
Streptococci, EBV and respiratory syncytial virus (RSV). 
The three other strains of HCoVs, severe acute respiratory 
syndrome coronavirus (SARS-CoV), Middle East respiratory 
syndrome coronavirus (MERS-CoV), and severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2), have a 
different pathogenicity and lead to higher mortality rates in 
human populations. MERS-CoV was isolated from a male 
patient who died from acute pneumonia and renal failure in 
Saudi Arabia in 201212. 
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CoVs is the largest known genome among RNA viruses 
contains an envelope with a non-segmented, positive-sense, 
single-strand RNA, with size ranging from 26,000 to 37,000 
bases13. All coronavirus genomes are arranged similarly with 
the replicase locus encoded within the 5’ end and the 
structural proteins encoded in the 3’ third of the genome 
arranged in the order hemagglutinin esterase (HE), if present 
(HE is only present in some beta coronaviruses), spike (S), 
small membrane (E), membrane (M) and nucleocapsid (N) 
and internal (I) protein, encoded within the N gene. The 
nucleo capsid protein complexes with the genome RNA to 
form a helical capsid structure found within the viral 
envelope. Trimers of the spike protein form the peplomers 
embedded in the envelope giving the virion its corona or 
crown-like morphology. In some coronavirus virions, the HE 
protein forms smaller spikes on the membrane. M and E are 
also transmembrane proteins involved in virus 
assembly1.Fig. 1 
 
Fig.1: Coronavirus virion structure. 
3. Genetic Diversity 
The genome RNA shown in fig.2 is complexed with the N 
protein to form a helical cased within the viral membrane, 
HE, hemagglutinin-esterase; S, spike; E, small membrane 
envelope; M, membrane are all transmembrane proteins. The 
genomic structure of SARS-CoV-2 is 5′-UTR-orf1a-orf1ab-S 
(Spike)–E (Envelope)-M (Membrane)-N (Nucleocapsid)-
3′UTRpoly (A) tail. Accessory genes are interspersed within 
the structural genes at the 3′ end of genome. The pp1a 
protein encoded by the orf1a gene and the pp1ab protein 
encoded by the orf1ab gene contains 10 nsps (nsp1-nsp10). 
The pp1ab protein also includes nsp12-nsp16. 
The various CoVs of animal origin undergo evolution and 
genetic recombination, thereby resulting in mutated CoVs 
that may be highly pathogenic and potentially be more 
deadly to humans15. The mutation rate in the SARS-CoV 
genome was estimated to be 0.80–2.38 × 10−3 nucleotide 
substitutions per site per year, which are similar to that of 
other RNA viruses16. The various CoVs of animal origin 
undergo evolution and genetic recombination either within 
the host species or upon jumping from one species to 
another. Such changes thus have the potential to lead to 
variants that have high pathogenic potential when 
transmitted to humans17-19. Recently, two mutations of the S 
protein and N protein SARS-CoV-2 may explain its zoonotic 
transmission20. Genomic alignment of 54 SARS-CoV-2 
genomes identified two hotspots of hypervariability at 
positions 8789 (synonymous variant) and 28,151(Ser/Leu 
change), located in the polyprotein and ORF8 genes 
respectively21.
 
 
Fig. 2: Schematic diagram of the SARS-CoV-2 genome14. 
 
3. Mode of Transmission of Coronavirus 
SARS-CoV originated from bats of the Hipposideridae family 
before dissemination to humans22. CoVs can transmit across 
species barriers. The earliest patients infected with SARS-
CoV-2 in Wuhan ultimately caused the epidemic known as 
CoronaVirus Disease 2019 (COVID-2019)23. Some of these 
patients had a history of contact with a wholesale seafood 
market in the early stages, suggesting animal-to-person 
spread. Subsequently, a large number of patients reportedly 
did not have exposure to the markets, suggesting the 
development of person-to-person 24-27. 
There are three ways to transmit the virus, including28-30: 
1. Close person-to-person contact 
2. Aerosol transmission 
3. Transmission by touch  
It also thought that the virus to be transmitted to other 
people by31  
A respiratory droplet means coughing or sneezing. Droplet 
spread can occur when an infected person sneezes or 
coughs, whereupon virus containing droplets are propelled 
up to 3 feet through the air and are deposited on the mucous 
membranes of the mouth, nose, or eyes of persons who are 
nearby.  
1. Transmission through the ocular surface is also 
possible.  
2. Shaking hands with an infected person,  
3. Touching an infected object/surface, 
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4. Frequent touching of the nose or mouth or coming into 
contact with a patient's excreta. 
5. Another way is through “hidden transmission”, in 
which asymptomatic infected individuals or carriers 
unknowingly transmit the virus to unsuspecting 
contacts. 
4. The pathogenesis of COVID-19 
Current understanding of the pathogenesis of HCoVs 
infection is still limited, especially for SARS-CoV-2. Before 
2019, there were six CoVs that could infect humans and 
cause respiratory disease. HCoV-229E, HCoV-OC43, HCoV-
NL63 and HCoV-HKU1 are sometimes attributed to the 
“common cold”, but in rare cases can cause severe infections 
in infants, young children and elderly people. On the other 
hand, SARS-CoV and MERS-CoV can infect the lower 
respiratory tract and cause a severe respiratory syndrome in 
human. The new coronavirus SARS-CoV-2 is similar to SARS-
CoV and MERS-CoV and can infect lower respiratory tract 
and cause severe pneumonia. 
The origin of SARS-CoV-2 was thought to be wild animals in 
the Huanan Seafood Market in Wuhan. However, not all 
cases have an apparent connection with the Wuhan Huanan 
Seafood Wholesale Market. It is evident now that SARS-CoV-
2 is capable of person-person transmission. We list the 
major pathogenic CoVs in Table 1 for better understanding 
of the pathogenesis of HCoV32. 
The term “cell pyroptosis” was first proposed in 200133. In 
recent decades, there has been increasing evidence 
suggesting that “pyroptosis” is a novel inflammatory form of 
programmed cell death. In 2019, Chen et al. found that SARS-
CoV Viroporin 3a triggered the activation of the NLRP3 
inflammasome and the secretion of IL-1β in bone marrow-
derived macrophages, suggesting SARS-CoV induced cell 
pyroptosis34 The pathways involved in the activation of the 
signaling between NLRP3m IL-1β, IL-18 and GSDMD are 
illustrated in Fig. 3 and are a subject of study in samples 
from SARS-CoV-2 patients35. 
The COVID-19 may be linked to cell pyroptosis, especially in 
lymphocytes through the activation of the NLRP3 
inflammasome. Morphological changes in lymphocytes and 
macrophages, nucleic acid and protein levels in classical and 
non-classical cells, detection of NLRP3 and GSDMD, and the 
role of inflammatory cytokines IL-1β and IL-18 requires 
further research. 
 
Table 1: Partial list of important pathogenic human coronaviruses 
Virus Genus Symptoms 
HCoV-229E alpha mild respiratory tract infections 
HCoV-NL63 alpha mild respiratory tract infections 
HCoV-OC43 beta mild respiratory tract infections 
HCoV-HKU1 beta pneumonia 
SARS-CoV beta severe acute respiratory syndrome, 11% mortality rate 
MERS-CoV beta severe acute respiratory syndrome, 34% mortality rate 
SARS-CoV-2 beta severe acute respiratory syndrome, 2.6% mortality rate 
 
 
 
Fig. 3: A hypothesis of the relationship between SARS-
CoV-2 and cell pyroptosis 
5. Clinical Manifestation 
The patients with SARS-CoV-2 shows a wide range of clinical 
manifestations are seen in from mild, moderate, to severe 
and rapidly progressive. Most of the patients with SARS-CoV-
2 were normal and mild, and their mortality was lower than 
SARS-CoV and MERS-CoV. 
5.1 Transmission: person-to-person, primarily via 
respiratory droplets (sneezing and coughing)  
 Direct contact transmission: especially hand-to-face 
contact  
 Fomite transmission: not documented but conceivably 
possible, especially with objects and surfaces that may 
have recently come into contact with infected 
individuals  
 Transmission via mail and packaged (imported) goods: 
There is no evidence to suggest that mail and packaged 
(imported) goods pose a risk for the spread of COVID-
19. 
 Fecal-oral transmission: Evidence that both SARS-CoV 
and MERS-CoV are excreted fecally suggests that fecal-
oral transmission is possible36.  
5.2 Incubation Period 
The mean incubation period of CoVID-19 was a little bit 
different. The study with 138 patients, reported that the 
median durations from first symptoms to dyspnea, hospital 
admission, and Acute severe respiratory syndrome (ARDS) 
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were 5 days (range, 1-10), 7 days (range, 4-8), and 8 days 
(range, 6-12), respectively37. The mean time from symptom 
onset to hospitalization was between 2 and 8 days, but was 
shorter toward the later phase of the epidemic. The mean 
time from symptom onset to need for invasive mechanical 
ventilation (IMV) and to death was 11 and 23.7 days, 
respectively38. 
5.3 Symptom of CoVID-19 
Symptom of CoVID-19 can range from no symptoms 
(asymptomatic) to severe pneumonia and death. The 
patients were initially diagnosed with the outbreak found 
that the most common symptoms were fever (98%), cough 
(76%), myalgia or fatigue (44%), and atypical symptoms 
included sputum (28%), headache (8%), hemoptysis (5%) 
and diarrhea (3%). About half of the patients had dyspnea 
(the median from onset to dyspnea was 8 days). 
Lymphocytopenia was observed in 63% of patients. All 
patients had pneumonia.  
Complications included acute respiratory distress syndrome 
(29%), acute heart injury (12%), and secondary infections 
(10%); 32% of patients require to be treated in the ICU39. 
The patients presented ground-glass shadow on chest CT. 
Recent studies indicate that patients≥60 years of age are at 
higher risk than children who might be less likely to become 
infected or, if so, may show milder symptoms or even 
asymptomatic infection40.  
Before the first outbreak of SARS, a limited number of HCoVs 
such as HCoV-229E were frequently found to infect humans, 
and were widely circulating in human populations causing 
only mild illnesses like the common cold. However, SARS, 
MERS and SARS-CoV-2 present with a spectrum of disease 
severity ranging from flu-like symptoms to acute respiratory 
distress syndrome41, 42. 
6. Early Detection and Diagnosis 
The SARS-CoV-2 infected cases have symptoms like fever, 
fatigue, dry cough, dyspnea etc., with or without nasal 
congestion, runny nose or other upper respiratory 
symptoms. Early identification of suspect cases is the key to 
inhibiting the spread of the virus. Rapid identification of the 
viral genome and the development of rapid diagnostic tests 
will facilitate the isolation of those who are confirmed as 
infected43. 
Diagnostic criteria44-50 
The diagnostic criteria of suspected and confirmed cases 
were summarized in Table 2. 
 
Table 2. The diagnostic criteria for suspected and confirmed cases  
Case Diagnostic criteria 
Suspected case Anyone with a history of epidemiology and any two of the clinical manifestations or anyone without 
epidemiological history and three of the clinical manifestations is considered to be a suspected case: 
(1) Epidemiological history: 
1) within 14 days before the disease onset, there is a travel history or living history in Wuhan or other 
areas with local cases 
2) within 14 days before the disease onset, there is contact with patients who had fever or respiratory 
symptoms from Wuhan or other areas with local cases 
3) a clustering of patients or a contact with patients infected with the SARS-CoV-2 
(2) Clinical manifestations: 
1) fever and/or respiratory symptoms 
2) with the above-mentioned imaging characteristics of pneumonia 
3) the total number of leukocytes in the early stage of the disease is normal or decreased, or the 
lymphocyte count is decreased 
Confirmed case Any suspected case with one of the following pathogenic features is reclassified as a confirmed case: 
(1) Positive results of SARS-CoV-2 nucleic acids by RT-PCR* of respiratory or blood specimens 
(2) DNA highly homologous to SARS-CoV-2 by genetic sequencing of viral genes in respiratory or blood 
specimens 
*RT-PCR: real-time reverse-transcriptase polymerase-chain-reaction. 
 
6.1 Physical examination 
Patients with mild symptoms may not be present positive 
signs. Patients in severe condition may have shortness of 
breath, moist rales in lungs, weakened breath sounds, 
dullness in percussion, and increased or decreased tactile 
speech tremor, etc. 
6.2 CT imaging examination 
The imaging finding vary with the patient`s age, immunity 
status, disease stage at the time of scanning, underlying 
diseases, and drug interventions. Chest X-ray examination In 
the early stage of pneumonia cases, chest images show 
multiple small patchy shadows and interstitial changes51, 
Severe cases can further develop to bilateral multiple 
ground-glass opacity, infiltrating shadows, and pulmonary 
consolidation, with infrequent pleural effusion. 
6.3 Laboratory Diagnosis 
Laboratory diagnosis mainly used to distinguished from 
other known viral virus of pneumonia, such as parainfluenza 
virus, influenza viruses, respiratory syncytial virus, 
rhinovirus, SARS-CoV,adenovirus, etc.; and also, from 
chlamydia pneumonia, mycoplasma pneumonia, and 
bacterial pneumonia. In addition, it should be distinguished 
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from non-infectious diseases, such as 
dermatomyositis,vasculitis, and organizing pneumonia52. So, 
laboratory diagnosis is necessary. Identification of CoVID-19 
mainly includes virus isolation and viral nucleic acid 
detection. A variety of specimens (such as swabs, nasal 
swabs, nasopharynx or trachea extracts, sputum or lung 
tissue, blood and feces) were used for testing in timely 
manner, which gives a higher rate of positive detection of 
lower respiratory tract specimens53. The Patients suspected 
SARS-CoV-2 infection for diagnosis by real time RT-PCR 
method54. 
7. Prevention and Treatment of SARS-CoV-2 
infection 
Novel coronavirus infection is a new communicable disease 
which affects almost all populations with all age group55. 
SARS-CoV-2 infection has been classified as category B 
infectious disease legally but managed as category A 
infectious disease by Chinese government. It is paramount to 
implement infection control practices by infection source 
controlling, transmission route blocking, and susceptible 
population protection. The unprecedented flurry of activity 
by WHO and other global public health bodies has mainly 
focused on preventing transmission, infection control 
measures, and screening of travelers56. 
There is no clear, unified and effective treatment plan for 
COVID-19. Most guidelines emphasize early identification, 
early isolation, early diagnosis, and early treatment. The 
treatment and management of SARS-CoV-2 pneumonia 
mainly include the following aspects57-61 Fig. 4. 
 
 
 
Fig. 4.  The treatment and management of COVID-19 pneumonia. ICU: intensive care unit; ECMO: extracorporeal 
membrane oxygenation 
 
7.1 General protective measures  
1. Hand hygiene:  
 Hands should be washed with soap and water or 
disinfected with a virucidal hand disinfectant after 
contact with potentially virus-contaminated objects 
and infected persons  
 Avoid touching the face: i.e., the eyes, nose, and mouth. 
2. Respiratory hygiene and cough etiquette  
 Avoid coughing or sneezing in the direction of others! 
 Use tissues and discard these after use.  
 If tissues are unavailable, coughing and sneezing into 
the crook of the arm can help keep hands free of 
contamination. 
 Maintain 3–6 ft (at least an arm's length) distance to 
coughing or sneezing persons. 
3. Avoid exposure  
 Avoid crowds of people (public transport, train 
stations, airports, mass events). 
 Avoid travel to areas of outbreak. 
4. Masks  
 In individuals with confirmed and suspected infection: 
useful for preventing the diffusion of respiratory 
secretions, e.g., during patient transports 
 In healthcare facilities (HCFs) or home care settings: 
crucial for health workers and persons taking care of an 
infected individual in close settings (in a HCF or at 
home)  
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 Surgical masks do not provide adequate protection in 
the setting of invasive diagnostics or those at high risk 
of exposure.  
 N95 respirators and protective eyewear are 
recommended for health care personnel that are 
potentially exposed to airborne and fluid hazards (e.g., 
during invasive procedures).  
 Confirmed COVID-19 patients and PUIs can use 
standard N95 respirators. 
 If N95 respirator bottlenecks occur, unvalved N95 
respirators may be used with a face shield. 
 Respirators and masks should be used resourcefully 
with special consideration for HCF needs. 
 In the general population: Surgical masks are most 
likely ineffective and may even pose an additional risk 
of infection. 
7.2 Intensive care 
 Indications: Admit to ICU and initiate intubation if any 
of the following are present:  
o Signs of respiratory failure  
o Dyspnea with hypoxemia  
o Tachypnea (RR > 30/min)  
 Airway management: Considering health-care 
workers have an increased risk of developing COVID-
19, especially during high-risk procedures such as 
intubation, aerosol-generating procedures should be 
avoided whenever possible62-64.  
o Endotracheal intubation: Rapid-sequence induction is 
preferred, especially as it minimizes the spreading of 
infectious aerosols.  
o To avoid aerosolizing the virus, noninvasive 
ventilation, high-flow oxygen therapy, bronchoscopy, 
and nebulizer treatment should be avoided unless 
there is an absolute indication.  
 If NIPPV is indicated (e.g., COPD, asthma, DNI status): 
attempt with a helmet (vs. face mask) interface  
 Mechanical breathing: ventilation with lower tidal 
volumes (LTV) as with ARDS65  
o Moderate tidal volume (6 mL/kg) 
o Plateau pressure < 30 cm H2O  
o Permissive hypercapnia (target pH > 7.3)  
o PEEP and FiO2 settings: adjust as needed according to 
ARDSnet protocol66 
o See therapy of ARDS for more information. 
7.3 Medical therapy and Treatment 
Early on, these patients are usually treated with conventional 
medications which had no clinical benefit, resulting in spread 
to health care personnel. For those with flu-like symptoms or 
even more severe disease, it would not be immediately 
evident that this is an atypical and virulent form of a 
coronavirus. For comparison, influenza has an estimated 
mortality rate of 0.07%–0.2%. A high index of suspicion is 
helpful but not foolproof. 
The general strategies include bed rest and supportive 
treatment, including antiviral therapy67, antibioics 
application, immunomodulating therapy68, organ function 
support, respiratory support, bronchoalveolar lavage (BAL), 
blood purification and extracorporeal membrane 
oxygenation (ECMO)69. 
Potential target structures and agents: A variety of agents are 
being tested, and clinical studies are being conducted70, 71.  
o Inhibition of adhesion and invasion  
 Camostat (protease inhibitor)  
o Inhibition of fusion  
 Chloroquine or less toxic hydroxychloroquine72-75  
 Hydroxychloroquine In combination with azithromycin 
is being intensely tested76 
 Umifenovir77 
o Inhibition of protease  
 Lopinavir/ritonavir78-80 
 Darunavir/ritonavir (possibly in combination with 
umifenovir)  
 Remdesivir81, 82 
o RNA polymerase inhibitors and nucleotide analogs  
 Favipiravir 83 (brand name: Avigan®; approved in 
Japan)  
 Remdesivir 81, 82 
 Baloxavir marboxil  
o Antibody therapy and biologicals 84  
 Tocilizumab, especially in the phase of ARDS when IL-6 
and CRP are increased 85  
 Recombinant ACE2 (rhACE2, APN01) 86 
o Passive immunization through serum therapy: 87  
 Immunized individuals (already had COVID-19) donate 
serum 
 Especially a potential option for risk groups 
7.3.1 Antiviral therapy  
To date, there is no anti-viral therapeutics that specifically 
targets human coronaviruses, so treatment is only 
supportive. In vitro, interferons (IFNs) are only partially 
effective against coronaviruses. In vivo, the effectiveness of 
IFNs combined with ribavirin requires further evaluation. A 
variety of other agents, including antiviral peptides and 
corticosteroids have been shown to be effective in vitro 
and/or in animal models. However, clinical evidence does 
not support the use of corticosteroid treatment for SARS-
CoV-2 lung injury.  
Antiviral agents and immunomodulators tested against 
SARS-CoV in animals and in vitro shown in Table 388
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Table 3.  Antiviral agent(s) and/or immunomodulator(s) Used in Treatment of Covid- 19 
Antiviral agent(s) and/or 
immunomodulator(s) 
Study setting and 
methods (virus strain) 
Main findingsa 
IFN-αB/D (hybrid IFN) BALB/c mice (Urbani) i.p. IFN-αB/D once daily for 3 days beginning 4 h after virus 
exposure reduced SARS-CoV replication in lungs by 1 log10 at 
10,000 and 32,000 IU; at the highest dose of 100,000 IU, virus lung 
titers were not detectable 
Ampligen [poly(I:C124)] 
(mismatched double-
stranded RNA IFN inducer) 
BALB/c mice (Urbani) i.p. Ampligen at 10 mg/kg 4 h after virus exposure reduced virus 
lung titers to undetectable levels 
Pegylated IFN-α as 
prophylactic treatment 
Cynomolgus macaques 
(Macaca fascicularis) 
(patient 5668) 
Significantly reduced viral replication and excretion, viral antigen 
expression by type 1 pneumocytes, and pulmonary damage; 
postexposure treatment with pegylated IFN-α yielded 
intermediate results 
IFN-α2b (Intron A) Vero (FFM-1, HK 
isolate) 
Mean (SD) EC50 = 4,950 (890) IU/ml (SI of >2) for FFM-1 isolate; 
mean (SD) EC50 = 6,500 (980) IU/ml (SI of >105) for HK isolate 
 Caco2 (FFM-1, HK 
isolate) 
Mean (SD) EC50 = 1,530 (220) IU/ml (SI of >6.5) for FFM-1 isolate; 
mean (SD) EC50 = 880 (130) IU/ml (SI of >11.4) for HK isolate 
IFN-β1b (Betaferon) Vero (FFM-1, HK 
isolate) 
Mean (SD) EC50 = 95 (17) IU/ml (SI of >105) for FFM-1 isolate; 
mean (SD) EC50 = 105 (21) IU/ml (SI of >95) for HK isolate 
 Caco2 (FFM-1, HK 
isolate) 
Mean (SD) EC50 = 21 (3.9) IU/ml (SI of >476) for FFM-1 isolate; 
mean (SD) EC50 = 9.2 (2.1) IU/ml (SI of >1,087) for HK isolate 
IFN-γ1b (Imukin) Vero (FFM-1, HK 
isolate) 
Mean (SD) EC50 = 2,500 (340) IU/ml (SI of >4) for FFM-1 isolate; 
mean (SD) EC50 = 1,700 (290) IU/ml (SI of >5.9) for HK isolate 
 Caco2 (FFM-1, HK 
isolate) 
Mean (SD) EC50 = >10,000 IU/ml (SI NA) for FFM-1 isolate; mean 
(SD) EC50 = >10,000 IU/ml (SI NA) for HK isolate 
IFN-β1a Vero E6 (Tor2, Tor7, 
and Urbani) 
IFN with p.i. IC50 = 50 IU/ml; IFN added postinfection IC50 = 500 
IU/ml 
IFN-β, IFN-α, IFN-γ Vero, MxA-expressing 
Vero (FFM-1) 
SARS-CoV strongly inhibited by IFN-β (with p.i.) and less so with 
IFN-α and IFN-γ; MxA does not interfere with viral replication 
IFN-α, IFN-β FRhK-4 (NMf) ↓ intracellular viral RNA copies; IFN-α IC50 = 25 U/ml; IFN-β IC50 = 
14 U/ml 
IFN-α2b Vero E6 (Tor2, Tor3, 
Tor7, and Tor684) 
IC50 = ∼500 IU/ml 
Leu-IFN-α FRhK-4 (HKU39849) EC50 at 48 h = 5,000 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 19.5 μg/ml 
IFN-α (p.i. for 16 h before 
viral inoculation) 
FRhK-4 (HKU39849) EC50 at 48 h = 39 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 19.5 μg/ml 
IFN-β FRhK-4 (HKU39849) EC50 at 48 h = 200 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 106 μg/ml 
IFN-β (p.i. for 16 h before 
viral inoculation) 
FRhK-4 (HKU39849) EC50 at 48 h = 625 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 19.5 μg/ml 
IFN-β1b (Betaferon) Vero E6 
(2003VA2774) 
IC50 = 0.2 IU/ml; IC95 = 8 IU ml 
IFN-αn3 (Alferon) Vero E6 
(2003VA2774) 
IC50 = 0.8 IU/ml; IC95 = 200 IU/ml 
Human leukocyte IFN-α 
(Multiferon) 
Vero E6 
(2003VA2774) 
IC50 = 2 IU/ml; IC95 = 44 IU/ml 
IFN-β Vero E6 (FFM-1) IC50 = 110 IU/ml at 10 TCID50; IC50 = 625 IU/ml at 100 TCID50 
Multiferon Vero E6 (FFM-1) IC50 = 540 IU/ml at 10 TCID50; IC50 = 2,400 IU/ml at 100 TCID50 
IFN-α2b Vero E6 (FFM-1) IC50 = >3,125 IU/ml at 10 TCID50; IC50 = >3,125 IU/ml at 100 
TCID50 
IFN-α2a Vero E6 (FFM-1) IC50 = >3,125 IU/ml at 10 TCID50; IC50 = >3,125 IU/ml at 100 
TCID50 
IFN-alfacon1 (Infergen) Vero (Urbani) IC50 = 0.001 μg/ml 
IL-4 and IFN-γ Vero E6 (HKU39849) IL-4 and IFN-γ downregulated cell surface expression of ACE2; 
ACE2 mRNA levels were also decreased after treatment 
IFN-β and ribavirin Caco2 (FFM-1) Mean (SD) CI = 0.45 (0.07) 
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HR2-8 (HR2-derived 
peptide) 
Vero 118 (NM) EC50 = 17 μM 
CP-1 (HR2-derived peptide) Vero E6 (WHU) IC50 ≈ 19 μmol/liter 
HR1-1 (HR1-derived 
peptide) 
Vero E6 (BJ01 and 
pseudovirus) 
EC50 = 3.68 μM for wild-type virus assay; EC50 = 0.14 μM for 
pseudotyped virus assay 
HR2-18 (HR2-derived 
peptide) 
Vero E6 (BJ01 and 
pseudovirus) 
EC50 = 5.22 μM for wild-type virus assay; EC50 = 1.19 μM for 
pseudotyped virus assay 
HR2 Vero E6 (WHU) CPE inhibition IC50 = 0.5-5 nM (synthetic HR2 peptide) and 66.2-
500 nM (fusion HR2 peptide) 
Peptides representing 
various regions of ACE2 
TELCeB6, HeLa, and 
VeroE6 (pseudovirus) 
IC50 = 50 μM (peptide aa 22-44); IC50 = 6 μM (peptide aa 22-57); 
IC50 = 0.1 μM (peptide aa 22-44 and 351-357) artificially linked by 
glycine 
Peptides analogous to viral 
spike protein 
Vero E6, L2 (Urbani) Inhibit viral plaque formation by 40-70% at 15-30 μM; peptides 
analogous to regions of the N terminus or the pretransmembrane 
domain of the S2 subunit; inhibit viral plaque formation by >80% 
at 15-30 μM (peptides analogous to the SARS-CoV loop region) 
siRNA, RL004, RL005 Vero E6 (Y3) siRNA (600 pmol/liter) targeting conserved regions of SARS-CoV, ↓ 
virally induced CPE at 67 h 
siRNA FRhK-4 (HKU66078) siRNA duplexes targeting regions in entire viral genome, ↓ virally 
induced CPE and viral production at 72 h 
siRNA targeting viral RP Vero (NM) ↓ virally induced CPE, ↓ viral production, ↓ viral protein synthesis 
at 1.5 or 3 μg of siRNA 
RNA interference targeting 
viral RP 
Vero E6, 293, HeLa 
(SARS-CoV-p9) 
↓ expression of RP (293 and HeLa cells); ↓ plaque formation at 1 μg 
of siRNA 
siRNA targeting S gene Vero E6, 293T (BJ01) ↓ S gene expression in SARS-CoV-infected cells at 2, 3, and 4 μg of 
siRNA 
siRNAs targeting S gene and 
3′ untranslated region 
Vero E6 (HK strain) ↓ viral antigen synthesis of 64% (by siSARS-S2), 51% (siSARS-S3), 
40% (siSARS 3′ untranslated region) at 100 pmol of siRNA 
Glycyrrhizin Vero (FFM-1, FFM-2) CPE assay mean (SD) CC50 = >20,000 mg/liter; EC50 = 300 (51) 
mg/liter (SI of >67) 
 FRhK-4 (HKU39849) EC50 at 48 h = >400 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 100 μg/ml 
Mizoribine Vero E6 (FFM-1) IC50 = 3.5 μg/ml; CC50 = >200 μg/ml 
 Vero E6 (HKU39489) IC50 = 16 μg/ml 
Ribavirin Vero E6 (FFM-1) IC50 = 20 μg/ml; CC50 = >200 μg/ml 
 Vero E6 (HKU39489) IC50 = 80 μg/ml 
 FRhK-4 (HKU39849) EC50 at 48 h = 50-100 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = >200 μg/ml 
Rimantidine FRhK-4 (HKU39849) EC50 at 48 h = 16 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 8-16 μg/ml 
Lopinavir FRhK-4 (HKU39849) EC50 at 48 h = 16 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 8-16 μg/ml 
Baicalin FRhK-4 (HKU39849) EC50 at 48 h = 12.5 μg/ml 
 Vero E6 (HKU39849) EC50 at 48 h = 100 μg/ml 
Aurintricarboxylic acid Vero (NM) EC50 = 0.2 mg/ml; CC50 = 37.5 mg/ml; SI = 187 
Reserpine Vero E6 (HK strain) EC50 = 3.4 μM; CC50 = 25 μM; SI = 7.3 
Aescin Vero E6 (HK strain) EC50 = 6 μM; CC50 = 15 μM; SI = 2.5 
Valinomycin Vero E6 (HK strain) EC50 = 0.85 μM; CC50 = 68 μM; SI = 80 
Niclosamide Vero E6 (Taiwan 
strain) 
EC50 = 1-3 μM; CC50 = 250 μM 
Nelfinavir Vero E6 (FFM-1) Mean (SD) EC50 = 0.048 (0.024) μM; CC50 = 14.75 (2.75) μM; SI = 
302.1 
Chloroquine Vero E6 (FFM-1) Mean (SD) IC50 = 8.8 (1.2) μM; CC50 = 261.3 (14.5) μM; SI = 30 
 Vero E6 (Urbani) Mean (SD) EC50 = 4.4 (1.0) μM; refractory to infection if pretreated 
with chloroquine (10 μM) for 20 h 
Indomethacin Vero E6 (Tor2) IC50 = 50 μM 
3C-like proteinase inhibitors   
Cinanserin (SQ 10,643)     Vero (NM) IC50 = 5 μM 
TG-0205221     Vero E6 (NM) ↓ viral load by 4.7 logs at 5 μM 
Octapeptide AVLQSGFR     Vero (BJ01) EC50 = 0.027 mg/liter; CC50 = >100 mg/liter; SI = >3,704 
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Peptidomimetic inhibitor     NM IC50 = 45-70 μM 
Calpain inhibitors, Val-Leu-
CHO 
Vero E6 (Urbani) EC90 = 3 μM 
Calpain inhibitors, Z-Val-
Phe-Ala-CHO 
Vero E6 (Urbani) EC90 = 15 μM 
Cyclopentenyl carbocyclic 
nucleosides 
NM EC50 = 47 μM for 1,2,3-triazole analogue (17c); EC50 = 21 μM for 
1,2,4-triazole analogue (17a) 
Nucleoside analogue 
inhibitor, β-d-N4-
hydroxycytidine 
Vero E6 (Urbani) EC90 = 6 μM 
Nitric oxide, S-nitroso-N-
acetylpenicillamine 
Vero E6 (FFM-1) Mean (SD) IC50 = 222 (83.7) μM; SI = 3 
Pyridine N-oxide derivatives Crandel feline kidney 
(CRFK) and Vero 
(FFM-1) 
Among 192 compounds tested, the oxide part on pyridine moiety 
was indispensable for antiviral activity with CC50 of 50-100 
mg/liter 
Stilbene derivatives Vero E6 (NM) Inhibited by compounds 17 and 19 at 0.5 mg/ml, and no significant 
cytotoxic effects were observed in vitro 
Peptide-conjugated 
antisense morpholino 
oligomers (P-PMO) 
Vero E6 (Tor2) Several virus-targeted P-PMO (AUG1, AUG2, AUG3, 1AFBS, and 
3UTR) consistently reduced CPE at a concn of 20 μM 
20-mer synthetic peptides (S 
protein fragments) 
FRhK-4 (GZ50) IC50 = 24.9-113 μg/ml; IC90 = 0.9-15.9 μg/ml 
Diverse small molecules,b 
MP576, HE602, and VE607 
Vero (HKU39849) EC50 = <10 μM 
Adamantane-derived 
compoundsc 
FRhK-4 (NM) IC50 = 0.5-3 μM; CC50 = >300 μM 
Semisynthetic derivatives of 
glycopeptide 
  
Vancomycin     Vero E6 (FFM-1) EC50 = 22->100 μM; CC50 = >80 μM 
Eremomycin     Vero E6 (FFM-1) EC50 = 14->100 μM; CC50 = 45->100 μM 
Teicoplanin, ristocetin A, 
and DA-40926     
Vero E6 (FFM-1) EC50 = >80 μM; CC50 = >80 μM 
Lycoris radiata (Chinese 
medicinal herb) 
Vero E6 (BJ001, BJ006) Mean (SD) EC50 = 2.4 (0.2) μg/ml; CC50 = 886.6 (35.0) μg/ml 
Artemisia annua (Chinese 
medicinal herb) 
Vero E6 (BJ001, BJ006) Mean (SD) EC50 = 34.5 (2.6) μg/ml; CC50 = 1,035 (92.8) μg/ml 
Pyrrosia lingua (Chinese 
medicinal herb) 
Vero E6 (BJ001, BJ006) Mean (SD) EC50 = 43.2 (14.1) μg/ml; CC50 = 2,378 (87.3) μg/ml 
Lindera sp. (Chinese 
medicinal herb) 
Vero E6 (BJ001, BJ006) Mean (SD) EC50 = 88.2 (7.7) μg/ml; CC50 = 1,374 (39.0) μg/ml 
 a i.p., intraperitoneal; EC50, 50% effective concentration; SI, selectivity index; NA, not available; p.i., preincubation; NM, not 
mentioned; IC50, 50% inhibitory concentration; TCID50, 50% tissue culture infective dose; CI, combination index (combination 
index of <1 indicates synergism); CPE, cell culture cytopathic effect; aa, amino acids; RP, RNA polymerase; CC 50, 50% cytotoxic 
concentration; ↓, decreased. 
 b MP576, HE602, and VE607 were validated to be inhibitors of SARS-CoV Mpro, Hel, and viral entry, respectively. 
 c Bananin, iodobananin, vanillinbananin, and eubananin were effective inhibitors of the ATPase activity of the SCV helicase. 
 
7.3.2. Immuno enhancement therapy 
Synthetic recombinant interferon α has proven to be effective 
in treatment of SARS patients in clinic trials89. Pulmonary X-
ray abnormal remission time was reduced by 50% in the 
interferon-treated group compared with the glucocorticoid-
treated group alone. Interferon was also found to be an 
effective inhibitor of MERS-CoV replication90. Those findings 
suggested that interferon could be used in the treatment of 
COVID-19. Intravenous immunoglobulin might be the safest 
immunomodulator for long-term use in all ages, and could 
help to inhibit the production of proinflammatory cytokines 
and increase the production of anti-inflammatory mediators91. 
Moreover, Thymosin alpha-1 (Ta1) can be an immune booster 
for SARS patients, effectively controlling the spread of 
disease92. Intravenous immunoglobulin and Ta1 may also be 
considered as therapeutics for COVID-19. 
A retrospective review analyzed 21 patients in which 
tocilizumab was added to standard COVID-19 therapy.(25) 
Preliminary data suggest tocilizumab may have clinical benefit 
as adjunctive therapy. Tocilizumab is Interleukin-6 (IL-6) 
Receptor-Inhibiting Monoclonal Antibody  
that can cause Cytokine release syndrome may be a 
component of severe disease in COVID-19 patients93.The 
Mechanism of Action of  said that it inhibits IL-6-mediated 
signaling by competitively binding to both soluble and 
membrane-bound IL-6 receptors. IL-6 is a proinflammatory 
cytokine that is involved in diverse physiological processes 
such as T-cell activation, immunoglobulin secretion induction, 
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hepatic acute-phase protein synthesis initiation, and 
hematopoietic precursor cell proliferation and differentiation 
stimulation. IL-6 is produced by various cell types, including T- 
and B-cells, lymphocytes, monocytes, and fibroblasts. 
7.3.3. Convalescent plasma therapy 
When there are no sufficient vaccines and specific drugs, 
convalescent plasma therapy could be an effective way to 
alleviate the course of disease for severely infected patients94. 
Plasma collected from persons who have recovered from 
COVID-19 that may contain antibodies to SARS-CoV-2 Clinical 
trials are being conducted to evaluate the use of COVID-19 
convalescent plasma to treat patients with severe or 
immediately life-threatening COVID-19 infections.Moreover, 
from the perspective of immunology, most of the patients 
recovered from COVID-19 would produce specific antibodies 
against the SARS-CoV-2, and their serum could be used to 
prevent reinfection. At the same time, antibodies can limit the 
virus reproduction in the acute phase of infection and help 
clear the virus, which is conducive to the rapid recovery of the 
disease95.  
Corticosteroids therapy: Corticosteroid therapy is not 
recommended for viral pneumonia; however, use may be 
considered for patients with refractory shock or acute 
respiratory distress syndrome. 
7.3.4. Vaccine Development 
Vaccines that have been developed are either not effective, or 
in some cases have been reported to be involved in the 
selection of novel pathogenic CoVs via recombination of 
circulating strains Vaccine development can be a challenge. It 
is noteworthy that almost 20 years after SARS, there is still no 
vaccine for coronavirus. After SARS, development of a vaccine 
appeared to be the best approach to prevent future SARS-CoV 
epidemics. However, there were many obstacles in SARS 
vaccine development. Firstly, researchers did not have a 
comprehensive understanding of the pathogenic mechanism 
of SARS-CoV. Secondly, animal models of SARS-CoV infection 
could not simulate human disease because of an incongruent 
pathogenesis. Thirdly, in order to test the efficacy, many 
people must be tested in areas where the virus is endemic. 
Although several candidate vaccines against SARS-CoV have 
been produced and tested, at present, unfortunately, there is 
no FDA approved vaccine against SARS96. 
8.  Rigorous infection control 
1. Contact tracing, strict isolation of actively ill patients and 
quarantine of close contacts should be implemented 
early97. 
2. Environmental hygiene in medical sectors and personal 
hygiene of health care workers should be maintained98, 
99. 
3. Training in the use of personal protective equipment 
protects the safety of HCWs100. 
4. Establishing fever clinics, setting up designated hospital 
wards and SARS hospitals reduced human-to-human 
transmission101. 
5. Education of the public on communicable diseases and 
what measures to take on a personal basis to prevent 
spread. 
9. Conclusion and Recommendation 
Looking ahead, the most feasible options that should be 
further evaluated in clinical trials for the ongoing Covid 19 
epidemic. The COVID-19 pandemic is spreading across the 
globe at an alarming rate. It has caused more infections and 
deaths as compared with SARS or MERS. The rapid spread of 
disease warrants intense surveillance and isolation protocols 
to prevent further transmission. No confirmed medication or 
vaccine has been developed. Current treatment strategies are 
aimed at symptomatic care and oxygen therapy. Prophylactic 
vaccination is required for the future prevention of COV-
related epidemic or pandemic. To reduce the risk of 
transmission in the community, individuals should be advised 
or recommended to wash hands diligently, practice 
respiratory hygiene (eg, cover their cough), and avoid crowds 
and close contact with ill individuals, if possible. Facemasks 
are not routinely recommended for asymptomatic individuals 
to prevent exposure in the community. Social distancing is 
advised, particularly in locations that have community 
transmission. The strict control of cross-infection in medical 
institutions is also key to preventing the further spread of the 
epidemic. 
Acknowledgements 
The authors are thankful to Dr. Surendra Kumar Jain Director 
SIRTSP for their  
References 
1. Perlman S, Netland J. Coronaviruses post-SARS: update on 
replication and pathogenesis. Nature reviews microbiology. 2009; 
7:439-50. 
2. Yang D, Leibowitz JL. The structure and functions of coronavirus 
genomic 3′ and 5′ ends. Virus research. 2015 3; 206:120-33. 
3. Drosten C, Günther S, Preiser W, Van Der Werf S, Brodt HR, Becker 
S, Rabenau H, Panning M, Kolesnikova L, Fouchier RA, Berger A. 
Identification of a novel coronavirus in patients with severe acute 
respiratory syndrome. New England journal of medicine. 2003; 
348:1967-76. 
4. Cotten M, Lam TT, Watson SJ, Palser AL, Petrova V, Grant P, Pybus 
OG, Rambaut A, Guan Y, Pillay D, Kellam P. Full-genome deep 
sequencing and phylogenetic analysis of novel human 
betacoronavirus. Emerging infectious diseases. 2013; 19:736. 
5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi 
W, Lu R, Niu P. A novel coronavirus from patients with pneumonia 
in China, 2019. New England Journal of Medicine. 2020:24. 
6. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic 
coronaviruses. Nature reviews Microbiology. 2019; 17:181-92. 
7. Maclachlan NJ, Dubovi EJ, editors. Fenner's veterinary virology. 
Academic press; 2010:26. 
8. Su S, Wong G, Shi W, Liu J, Lai AC, Zhou J, Liu W, Bi Y, Gao GF. 
Epidemiology, genetic recombination, and pathogenesis of 
coronaviruses. Trends in microbiology. 2016; 24:490-502. 
9. Khan S, Siddique R, Shereen MA, Ali A, Liu J, Bai Q, Bashir N, Xue M. 
The emergence of a novel coronavirus (SARS-CoV-2), their biology 
and therapeutic options. Journal of clinical microbiology. 2020. 
10. Isaacs D, Flowers D, Clarke JR, Valman HB, MacNaughton MR. 
Epidemiology of coronavirus respiratory infections. Archives of 
disease in childhood. 1983; 58:500-3. 
11. Greenberg SB. Update on human rhinovirus and coronavirus 
infections. InSeminars in respiratory and critical care medicine 
2016;37: 555-571. 
12.  Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, 
Fouchier RA. Isolation of a novel coronavirus from a man with 
pneumonia in Saudi Arabia. New England Journal of Medicine. 
2012; 367:1814-20. 
13. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the 
emerging pathogen severe acute respiratory syndrome 
coronavirus. Microbiol. Mol. Biol. Rev. 2005; 69:635-64. 
14. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, 
Zhang Z, Wang J, Sheng J. Genome composition and divergence of 
the novel coronavirus (2019-nCoV) originating in China. Cell host 
& microbe. 2020. 
15.  Sabir JS, Lam TT, Ahmed MM, Li L, Shen Y, Abo-Aba SE, Qureshi 
MI, Abu-Zeid M, Zhang Y, Khiyami MA, Alharbi NS. Co-circulation 
of three camel coronavirus species and recombination of MERS-
CoVs in Saudi Arabia. Science. 2016; 35:81-4. 
16. Zhao Z, Li H, Wu X, Zhong Y, Zhang K, Zhang YP, Boerwinkle E, Fu 
YX. Moderate mutation rate in the SARS coronavirus genome and 
its implications. BMC evolutionary biology. 2004; 4:21. 
Jain et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2020; 10(3):241-252 
ISSN: 2250-1177                                                                                  [251]                                                                                 CODEN (USA): JDDTAO 
17.  Woo PC, Lau SK, Yuen KY. Infectious diseases emerging from 
Chinese wet-markets: zoonotic origins of severe respiratory viral 
infections. Current opinion in infectious diseases. 2006; 19:401-7. 
18. Woo PC, Lau SK, Huang Y, Yuen KY. Coronavirus diversity, 
phylogeny and interspecies jumping. Experimental Biology and 
Medicine. 2009; 234:1117-27.  
19. Woo PC, Lau SK, Yip CC, Huang Y, Tsoi HW, Chan KH, Yuen KY. 
Comparative analysis of 22 coronavirus HKU1 genomes reveals a 
novel genotype and evidence of natural recombination in 
coronavirus HKU1. Journal of virology. 2006; 80:7136-45. 
20. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, 
Ciccozzi M. The 2019‐new coronavirus epidemic: evidence for 
virus evolution. Journal of Medical Virology. 2020; 92:455-9. 
21.  Ceraolo C, Giorgi FM. Genomic variance of the 2019‐nCoV 
coronavirus. Journal of Medical Virology. 2020. 
22.  Lau SK, Li KS, Huang Y, Shek CT, Tse H, Wang M, Choi GK, Xu H, 
Lam CS, Guo R, Chan KH. Ecoepidemiology and complete genome 
comparison of different strains of severe acute respiratory 
syndrome-related Rhinolophus bat coronavirus in China reveal 
bats as a reservoir for acute, self-limiting infection that allows 
recombination events. Journal of virology. 2010; 84:2808-19. 
23. Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, 
Hu Z, Zhang H, Zhang J: Bats are natural reservoirs of SARS-like 
coronaviruses. Science 2005; 310:676-9. 
24. Lu H, Stratton CW, Tang YW: Outbreak of Pneumonia of Unknown 
Etiology in Wuhan China: the Mystery and the Miracle. Journal of 
Medical Virology. 
25.  Ji W, Wang W, Zhao X, Zai J, Li X. Cross‐species transmission of the 
newly identified coronavirus 2019‐nCoV. Journal of medical 
virology 2020: 433-40. 
26. J Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip 
CC, Poon RW, Tsoi HW. A familial cluster of pneumonia associated 
with the 2019 novel coronavirus indicating person-to-person 
transmission: a study of a family cluster. The Lancet. 2020; 
395:514-23. 
27. Nishiura H, Linton NM, Akhmetzhanov AR. Initial cluster of novel 
coronavirus (2019-nCoV) infections in Wuhan, China is consistent 
with substantial human-to-human transmission.  J. Clin. Med., 
2020; 9:E488 
28. Organization, W.H., Consensus Document on the Epidemiology of 
Severe Acute Respiratory Syndrome (SARS). 2003, World Health 
Organization: Geneva. 
29. Maier HJ, Bickerton E, Britton P. Coronaviruses: methods and 
protocols. Springer Berlin; 2015: 1-282 
30. Malik M, Elkholy AA, Khan W, Hassounah S, Abubakar A, Minh NT, 
Mala P. Middle East respiratory syndrome coronavirus: current 
knowledge and future considerations. EMHJ-Eastern 
Mediterranean Health Journal. 2016; 22:533-42. 
31. Lu CW, Liu XF, Jia ZF. 2019-nCoV transmission through the ocular 
surface must not be ignored. The Lancet. 2020 Feb 22; 
395(10224):e39. 
32. Chen Y, Liu Q, Guo D. Emerging coronaviruses. genome structure, 
replication, and pathogenesis. Journal of medical virology. 2020; 
92:418-23. 
33.  Cookson BT, Brennan MA. Pro-inflammatory programmed cell 
death. Trends in microbiology. 2001; 3:113-4. 
34. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute 
respiratory syndrome coronavirus viroporin 3a activates the 
NLRP3 inflammasome. Frontiers in microbiology. 2019; 10. 
35. Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute 
respiratory syndrome coronavirus viroporin 3a activates the 
NLRP3 inflammasome. Frontiers in microbiology. 2019; 10. 
36. Yang M. Cell pyroptosis, a potential pathogenic mechanism of 
2019-nCoV infection. Available at SSRN 3527420. 2020. 
37. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is 
faecal–oral transmission of SARS-CoV-2 possible?. The Lancet 
Gastroenterology & Hepatology. 2020; 5:335-7. 
38. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng 
Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized 
patients with 2019 novel coronavirus–infected pneumonia in 
Wuhan, China. Jama. 2020. 
39. Leung GM, Hedley AJ, Ho LM, Chau P, Wong IO, Thach TQ, Ghani 
AC, Donnelly CA, Fraser C, Riley S, Ferguson NM. The 
epidemiology of severe acute respiratory syndrome in the 2003 
Hong Kong epidemic: an analysis of all 1755 patients. Annals of 
internal medicine. 2004; 141:662-73. 
40.  Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei 
CL, Hui DS, Du B. Clinical characteristics of 2019 novel 
coronavirus infection in China. MedRxiv. 2020. 
41. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau 
EH, Wong JY, Xing X. Early transmission dynamics in Wuhan, 
China, of novel coronavirus–infected pneumonia. New England 
Journal of Medicine. 2020. 
42.  Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as 
causes of pneumonia. Respirology. 2018; 23130-7. 
43.  Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu 
X, Cheng Z. Clinical features of patients infected with 2019 novel 
coronavirus in Wuhan, China. The Lancet. 2020; 395:497-506. 
44. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, 
Tong S, Urbani C, Comer JA, Lim W, Rollin PE. A novel coronavirus 
associated with severe acute respiratory syndrome. New England 
journal of medicine. 2003; 348:1953-66.  
45. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, 
Wei Y, Yu T. Epidemiological and clinical characteristics of 99 
cases of 2019 novel coronavirus pneumonia in Wuhan, China: a 
descriptive study. The Lancet. 2020; 395:507-13. 
46. Qiao J. What are the risks of COVID-19 infection in pregnant 
women?. The Lancet. 2020; 395:760-2. 
47. Yi Y, Lagniton PN, Ye S, Li E, Xu RH. COVID-19: what has been 
learned and to be learned about the novel coronavirus disease. 
International Journal of Biological Sciences. 2020; 16:1753. 
48. Shen K, Yang Y, Wang T, Zhao D, Jiang Y, Jin R, Zheng Y, Xu B, Xie Z, 
Lin L, Shang Y. Diagnosis, treatment, and prevention of 2019 novel 
coronavirus infection in children: experts’ consensus statement. 
World Journal of Pediatrics. 2020:1-9. 
49. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, 
Wang Y. Clinical course and outcomes of critically ill patients with 
SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, 
retrospective, observational study. The Lancet Respiratory 
Medicine. 2020. 
50.  Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan KS, Wang 
DY, Yan Y. The origin, transmission and clinical therapies on 
coronavirus disease 2019 (COVID-19) outbreak–an update on the 
status. Military Medical Research. 2020; 7:1-0. 
51. Ai S, Zhu G, Tian F, Li H, Gao Y, Wu Y, Liu Q, Lin H. Population 
movement, city closure and spatial transmission of the 2019-nCoV 
infection in China. medRxiv. 2020 Jan 1. 
52. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, Ling Y, Jiang Y, Shi Y. 
Emerging 2019 novel coronavirus (2019-nCoV) pneumonia. 
Radiology. 2020:200274. 
53. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, Fang C, Huang D, 
Huang LQ, Huang Q, Han Y. A rapid advice guideline for the 
diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) 
infected pneumonia (standard version). Military Medical 
Research. 2020; 7:4. 
54. Yu F, Du L, Ojcius DM, Pan C, Jiang S. Measures for diagnosing and 
treating infections by a novel coronavirus responsible for a 
pneumonia outbreak originating in Wuhan, China. Microbes and 
infection. 2020 Feb 1. 
55.  Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, 
Bleicker T, Brünink S, Schneider J, Schmidt ML, Mulders DG: 
Detection of 2019 novel coronavirus (2019-nCoV) by real-time 
RT-PCR. Eurosurveillance 2020;25.1-8 
56. Burki T. Outbreak of coronavirus disease 2019. The Lancet 
Infectious Diseases. 2020; 20:292-3. 
57. Yan Y, Shin WI, Pang YX, Meng Y, Lai J, You C, Zhao H, Lester E, Wu 
T, Pang CH. The First 75 Days of Novel Coronavirus (SARS-CoV-2) 
Outbreak: Recent Advances, Prevention, and Treatment. 
International Journal of Environmental Research and Public 
Health. 2020; 17:2323. 
58. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, Wang YY, Xiao GF, 
Yan B, Shi ZL, Zhou P. Molecular and serological investigation of 
2019-nCoV infected patients: implication of multiple shedding 
routes. Emerging microbes & infections. 2020; 9:386-9. 
59.  Yang Y, Peng F, Wang R, Guan K, Jiang T, Xu G, Sun J, Chang C. The 
deadly coronaviruses: The 2003 SARS pandemic and the 2020 
novel coronavirus epidemic in China. Journal of autoimmunity. 
2020:102434. 
60. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, Han Y, Lin L, Ruan L, Li 
T. High-dose intravenous immunoglobulin as a therapeutic option 
for deteriorating patients with Coronavirus Disease 2019. InOpen 
Forum Infectious Diseases 2020: 7. 
61. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona 
Jain et al                                                                                                                  Journal of Drug Delivery & Therapeutics. 2020; 10(3):241-252 
ISSN: 2250-1177                                                                                  [252]                                                                                 CODEN (USA): JDDTAO 
virus disease-2019 (COVID-19): the epidemic and the challenges. 
International journal of antimicrobial agents. 2020:105924. 
62. C.N.H. Commission New Coronavirus Pneumonia Prevention and 
Control Program (fifth ed.), China National Health Commission, 
2020, 2020.  
63. Chang D, Xu H, Rebaza A, Sharma L, Cruz CS. Protecting health-
care workers from subclinical coronavirus infection. The Lancet 
Respiratory Medicine. 2020; 8:e13. 
64. Cheung JC, Ho LT, Cheng JV, Cham EY, Lam KN. Staff safety during 
emergency airway management for COVID-19 in Hong Kong. The 
Lancet Respiratory Medicine. 2020. 
65. Wax RS, Christian MD. Practical recommendations for critical care 
and anesthesiology teams caring for novel coronavirus (2019-
nCoV) patients. Canadian Journal of Anesthesia/Journal canadien 
d'anesthésie. 2020:1-9. 
66.  Network AR. Brower RG, Matthay MA, Morris A, Schoenfeld D, 
Thompson BT, Wheeler A. Ventilation with lower tidal volumes as 
compared with traditional tidal volumes for acute lung injury and 
the acute respiratory distress syndrome. N engl J med. 2000; 
342:1301-8. 
67. ARDSnet. NIH NHLBI ARDS Clinical Network Mechanical 
Ventilation Protocol Summary., 2020.  
68. Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al 
Harbi S, Kojan S, Al Jeraisy M, Deeb AM, Assiri AM, Al-Hameed F: 
Treatment of Middle East Respiratory Syndrome with a 
combination of lopinavir-ritonavir and interferon-β1b (MIRACLE 
trial): study protocol for a randomized controlled trial Trials. 
2018:81:18 
69. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, 
Hussein MA, Jose J, Pinto R, Al-Omari A, Kharaba A, Almotairi A: 
Corticosteroid therapy for critically ill patients with Middle East 
respiratory syndrome. American journal of respiratory and 
critical care medicine 2018; 197:757-67. 
70. Chen ZM, Fu JF, Shu Q, Chen YH, Hua CZ, Li FB, Lin R, Tang LF, 
Wang TL, Wang W, Wang YS. Diagnosis and treatment 
recommendations for pediatric respiratory infection caused by 
the 2019 novel coronavirus. World Journal of Pediatrics. 2020:1-7. 
71.  Du L, He Y, Zhou Y, Liu S, Zheng BJ, Jiang S. The spike protein of 
SARS-CoV—a target for vaccine and therapeutic development. 
Nature Reviews Microbiology. 2009; 7:226-36. 
72. Lu H. Drug treatment options for the 2019-new coronavirus 
(2019-nCoV). Bioscience trends. 2020 Feb 29; 14:69-71. 
73. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, 
Song C, Zhan S. In vitro antiviral activity and projection of 
optimized dosing design of hydroxychloroquine for the treatment 
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2). Clinical Infectious Diseases. 2020. 
74. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine 
and hydroxychloroquine as available weapons to fight COVID-19. 
Int J Antimicrob Agents. 2020; 105932. 
75. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A 
systematic review on the efficacy and safety of chloroquine for the 
treatment of COVID-19. Journal of critical care. 2020. 
76. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, Li Y, Hu Z, Zhong W, 
Wang M. Hydroxychloroquine, a less toxic derivative of 
chloroquine, is effective in inhibiting SARS-CoV-2 infection in 
vitro. Cell discovery. 2020; 6:1-4. 
77. Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, 
Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S. 
Hydroxychloroquine and azithromycin as a treatment of COVID-
19: results of an open-label non-randomized clinical trial. 
International Journal of Antimicrobial Agents. 2020:105949. 
78. Xu K, Chen Y, Yuan J, Yi P, Ding C, Wu W, Li Y, Ni Q, Zhou R, Li X, Xu 
M. Clinical efficacy of Arbidol in patients with 2019 novel 
coronavirus-infected pneumonia: a retrospective cohort study. 
79. Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, 
Marimuthu K, Ang LW, Mak TM, Lau SK. Epidemiologic features 
and clinical course of patients infected with SARS-CoV-2 in 
Singapore. Jama. 2020. 
80. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, Kao RY, 
Poon LL, Wong CL, Guan Y, Peiris JS. Role of lopinavir/ritonavir in 
the treatment of SARS: initial virological and clinical findings. 
Thorax. 2004; 59(3):252-6. 
81. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, 
Wei M, Li X: A trial of lopinavir–ritonavir in adults hospitalized 
with severe Covid-19. New England Journal of Medicine 2020. 
82. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, 
Montgomery SA, Hogg A, Babusis D, Clarke MO, Spahn JE: 
Comparative therapeutic efficacy of remdesivir and combination 
lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature 
Communications 2020; 11:1-4. 
83. Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, 
Smith EC, Case JB, Feng JY, Jordan R, Ray AS. Coronavirus 
susceptibility to the antiviral remdesivir (GS-5734) is mediated by 
the viral polymerase and the proofreading exoribonuclease. MBio. 
2018; 9:e00221-18. 
84.  Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad 
spectrum inhibitor of viral RNA polymerase. Proceedings of the 
Japan Academy, Series B. 2017 Aug 2; 93(7):449-63. 
85. Wang C, Li W, Drabek D, Okba NM, van Haperen R, Osterhaus AD, 
van Kuppeveld FJ, Haagmans BL, Grosveld F, Bosch BJ. A human 
monoclonal 1 antibody blocking SARS-CoV-2 infection. Biorxiv. 
2020. 
86. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li 
X, Zhang X. Effective treatment of severe COVID-19 patients with 
Tocilizumab. ChinaXiv. 2020; 202003:v1. 
87.  Zhang H, Baker A. Recombinant human ACE2: acing out 
angiotensin II in ARDS therapy. Critical Care. 2017; 21.30-36  
88. Casadevall A, Pirofski LA. The convalescent sera option for 
containing COVID-19. The Journal of clinical investigation. 2020; 
130(4). 
89. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory 
syndrome coronavirus as an agent of emerging and reemerging 
infection. Clinical microbiology reviews. 2007; 20:660-94. 
90. Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, 
Pham DH, Deif H, LaMere EA, Chang M, Kain KC. Interferon 
alfacon-1 plus corticosteroids in severe acute respiratory 
syndrome: a preliminary study. Jama. 2003; 290:3222-8. 
91. Mustafa S, Balkhy H, Gabere MN. Current treatment options and 
the role of peptides as potential therapeutic components for 
Middle East Respiratory Syndrome (MERS): a review. Journal of 
infection and public health. 2018; 11:9-17. 
92. Gilardin L, Bayry J, Kaveri SV. Intravenous immunoglobulin as 
clinical immune-modulating therapy. Cmaj. 2015; 187:257-64. 
93.  Kumar V, Jung YS, Liang PH. Anti-SARS coronavirus agents: a 
patent review (2008–present). Expert opinion on therapeutic 
patents. 2013; 23:1337-48. 
94. Nicastri E, Petrosillo N, Bartoli TA, Lepore L, Mondi A, Palmieri F, 
D’Offizi G, Marchioni L, Murachelli S, Ippolito G, Antinori A. 
National Institute for the Infectious Diseases “L. Spallanzani”, 
IRCCS. Recommendations for COVID-19 clinical management. 
Infectious Disease Reports. 2020; 12. 
95.  Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, 
Lim WS, Makki S, Rooney KD, Convalescent Plasma Study Group, 
Nguyen-Van-Tam JS, Beck CR: The effectiveness of convalescent 
plasma and hyperimmune immunoglobulin for the treatment of 
severe acute respiratory infections of viral etiology: a systematic 
review and exploratory meta-analysis. The Journal of infectious 
diseases 2015; 211:80-90. 
96. Klimpel GR. Immune defenses. InMedical Microbiology. 4th 
edition 1996. University of Texas Medical Branch at Galveston. 
97. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY: Coronaviruses—drug 
discovery and therapeutic options. Nature reviews Drug discovery 
2016; 15:327. 
98. Abdullah AS, Tomlinson B, Cockram CS, Thomas GN. Lessons from 
the severe acute respiratory syndrome outbreak in Hong Kong. 
Emerging Infectious Diseases. 2003; 9:1042. 
99.  Wenzel RP, Edmond MB. Listening to SARS: lessons for infection 
control. Annals of internal medicine. 2003; 139:592-3. 
100. Cheng VC, Chan JF, To KK, Yuen KY. Clinical management 
and infection control of SARS: lessons learned. Antiviral research. 
2013; 100:407-19. 
101.  Parashar UD, Anderson LJ. Severe acute respiratory 
syndrome: review and lessons of the 2003 outbreak.  Int. J. 
Epidemiol., 2004;33: 628-634 
102. Pang X, Zhu Z, Xu F, Guo J, Gong X, Liu D, Liu Z, Chin DP, 
Feikin DR. Evaluation of control measures implemented in the 
severe acute respiratory syndrome outbreak in Beijing, 2003. 
Jama. 2003; 290:3215-21. 
 
 
